All In Biotech

Drug Trial Radar · NCT00483158

First Time in Man Study of Finafloxacin Hydrochloride

A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single and Multiple Oral Doses of Finafloxacin Hydrochloride in Healthy Subjects and a Study of H. Pylori Treatment in Healthy Carriers

Last checked: Nov 19, 2026Latest source record: Jul 29, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Aug 2007

Primary completion

May 2008

Study completion May 2008

Sponsor

Lead sponsor
MerLion Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Jun 6, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to study the safety of single doses and multiple doses of Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride will be measured in the subjects blood and urine. One part of the study will assess if Finafloxacin hydrochloride eradicates Helicobacter pylori, a stomach bacteria. Another part of the study will assess the activity of the drug in urine.

Conditions

  • Helicobacter Infections
  • Urinary Tract Infection

Interventions

  • Finafloxacin hydrochlorideDrug

    Tablets, oral single dose and multiple dose once daily for 7d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of single and multiple oral doses of Finafloxacin HCl by assessing adverse events, physical examinations, clinical chemistry examination, hematology, ECG and urinalysis.Time frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Swiss Pharma Contract Ltd

    Basel, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.